Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010 (2010), Article ID 985614, 8 pages
http://dx.doi.org/10.1155/2010/985614
Clinical Study

Redox Responses in Patients with Sepsis: High Correlation of Thioredoxin-1 and Macrophage Migration Inhibitory Factor Plasma Levels

1Department of Anaesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
2Department of Anaesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, 600 N Wolfe Street, Baltimore, MD 21287, USA
3Department of Anaesthesiology and Intensive Care Medicine, University of Giessen, Rudolf-Buchheim-Straße 7, 35392 Giessen, Germany
4Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
5Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
6Department of Medicine, Faculty of Clinical Medicine, University of Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

Received 22 February 2010; Accepted 30 June 2010

Academic Editor: Eeva Moilanen

Copyright © 2010 Thorsten Brenner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Alberti, C. Brun-Buisson, S. V. Goodman et al., “Influence of systemic inflammatory response syndrome and sepsis on outcome of critically III infected patients,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 1, pp. 77–84, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Annane, P. Aegerter, M. C. Jars-Guincestre, and B. Guidet, “Current epidemiology of septic shock: the CUB-Réa network,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 2, pp. 165–172, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Brun-Buisson, F. Doyon, J. Carlet et al., “Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units,” Journal of the American Medical Association, vol. 274, no. 12, pp. 968–974, 1995. View at Google Scholar
  4. C. Brun-Buisson, P. Meshaka, P. Pinton, and B. Vallet, “EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units,” Intensive Care Medicine, vol. 30, no. 4, pp. 580–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, “The epidemiology of sepsis in the United States from 1979 through 2000,” The New England Journal of Medicine, vol. 348, no. 16, pp. 1546–1554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001. View at Google Scholar · View at Scopus
  7. A. Burke-Gaffney, M. E. J. Callister, and H. Nakamura, “Thioredoxin: friend or foe in human disease?” Trends in Pharmacological Sciences, vol. 26, no. 8, pp. 398–404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Calandra, B. Echtenacher, D. Le Roy et al., “Protection from septic shock by neutralization of macrophage migration inhibitory factor,” Nature Medicine, vol. 6, no. 2, pp. 164–170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003. View at Google Scholar · View at Scopus
  10. M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference,” Critical Care Medicine, vol. 31, no. 4, pp. 1250–1256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” The New England Journal of Medicine, vol. 345, no. 19, pp. 1368–1377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Russell, “Management of sepsis,” The New England Journal of Medicine, vol. 355, no. 16, pp. 1699–1713, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Weigand, H. J. Bardenheuer, and B. W. Böttiger, “Clinical management of patients with sepsis,” Anaesthesist, vol. 52, no. 1, pp. 3–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Schouten, W. J. Wiersinga, M. Levi, and T. Van Der Poll, “Inflammation, endothelium, and coagulation in sepsis,” Journal of Leukocyte Biology, vol. 83, no. 3, pp. 536–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Weigand, H. Schmidt, M. Pourmahmoud, Q. Zhao, E. Martin, and H. J. Bardenheuer, “Circulating intercellular adhesion molecule-1 as an early predictor of hepatic failure in patients with septic shock,” Critical Care Medicine, vol. 27, no. 12, pp. 2656–2661, 1999. View at Google Scholar · View at Scopus
  16. E. A. Deitch, D. Xu, and V. L. Kaiser, “Role of the gut in the development of injury- and shock induced SIRS and MODS: the gut-lymph hypothesis, a review,” Frontiers in Bioscience, vol. 11, no. 1, pp. 520–528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Van Snick, “Interleukin-6: an overview,” Annual Review of Immunology, vol. 8, pp. 253–278, 1990. View at Google Scholar · View at Scopus
  18. K. Fassbender, H. Pargger, W. Muller, and W. Zimmerli, “Interleukin-6 and acute-phase protein concentrations in surgical intensive care unit patients: diagnostic signs in nosocomial infection,” Critical Care Medicine, vol. 21, no. 8, pp. 1175–1180, 1993. View at Google Scholar · View at Scopus
  19. J. Butler, G. L. Chong, R. J. Baigrie, R. Pillai, S. Westaby, and G. M. Rocker, “Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation,” Annals of Thoracic Surgery, vol. 53, no. 5, pp. 833–838, 1992. View at Google Scholar · View at Scopus
  20. P. Damas, D. Ledoux, M. Nys et al., “Cytokine serum level during severe sepsis in human IL-6 as a marker of severity,” Annals of Surgery, vol. 215, no. 4, pp. 356–362, 1992. View at Google Scholar · View at Scopus
  21. C. E. Hack, E. R. De Groot, R. J. F. Felt-Bersma et al., “Increased plasma levels of interleukin-6 in sepsis,” Blood, vol. 74, no. 5, pp. 1704–1710, 1989. View at Google Scholar · View at Scopus
  22. E. S. J. Arnér and A. Holmgren, “Physiological functions of thioredoxin and thioredoxin reductase,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6102–6109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Holmgren, “Antioxidant function of thioredoxin and glutaredoxin systems,” Antioxidants and Redox Signaling, vol. 2, no. 4, pp. 811–820, 2000. View at Google Scholar · View at Scopus
  24. A. Mitsui, T. Hirakawa, and J. Yodoi, “Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin,” Biochemical and Biophysical Research Communications, vol. 186, no. 3, pp. 1220–1226, 1992. View at Google Scholar · View at Scopus
  25. D. Mustacich and G. Powis, “Thioredoxin reductase,” Biochemical Journal, vol. 346, no. 1, pp. 1–8, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Tagaya, Y. Maeda, A. Mitsui et al., “ATL-derived factor (ADF), an IL-2 receptor/TAC inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction,” EMBO Journal, vol. 8, no. 3, pp. 757–764, 1989. View at Google Scholar · View at Scopus
  27. Y. Tagaya, H. Wakasugi, H. Masutani et al., “Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction,” Molecular Immunology, vol. 27, no. 12, pp. 1279–1289, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Hirota, M. Matsui, S. Iwata, A. Nishiyama, K. Mori, and J. Yodoi, “AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 3633–3638, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Hirota, M. Murata, Y. Sachi et al., “Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB,” Journal of Biological Chemistry, vol. 274, no. 39, pp. 27891–27897, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Powis and W. R. Montfort, “Properties and biological activities of thioredoxins,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 261–295, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Abdiu, H. Nakamura, B. Sahaf, J. Yodoi, A. Holmgren, and A. Rosén, “Thioredoxin blood level increases after severe burn injury,” Antioxidants and Redox Signaling, vol. 2, no. 4, pp. 707–716, 2000. View at Google Scholar · View at Scopus
  32. M. E. Callister, A. Burke-Gaffney, G. J. Quinlan et al., “Extracellular thioredoxin levels are increased in patients with acute lung injury,” Thorax, vol. 61, no. 6, pp. 521–527, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Jekell, A. Hossain, U. Alehagen, U. Dahlström, and A. Rosén, “Elevated circulating levels of thioredoxin and stress in chronic heart failure,” European Journal of Heart Failure, vol. 6, no. 7, pp. 883–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Jikimoto, Y. Nishikubo, M. Koshiba et al., “Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis,” Molecular Immunology, vol. 38, no. 10, pp. 765–772, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Kato, M. Odamaki, H. Nakamura, J. Yodoi, and A. Hishida, “Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection,” Kidney International, vol. 63, no. 6, pp. 2262–2268, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Miyazaki, N. Noda, S. Okada et al., “Elevated serum level of thioredoxin in patients with hepatocellular carcinoma,” Biotherapy, vol. 11, no. 4, pp. 277–288, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Nakamura, S. De Rosa, M. Roederer et al., “Elevation of plasma thioredoxin levels in HIV-infected individuals,” International Immunology, vol. 8, no. 4, pp. 603–611, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Gromer, S. Urig, and K. Becker, “The thioredoxin system—from science to clinic,” Medicinal Research Reviews, vol. 24, no. 1, pp. 40–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Nakamura, “Thioredoxin as a key molecule in redox signaling,” Antioxidants and Redox Signaling, vol. 6, no. 1, pp. 15–17, 2004. View at Google Scholar · View at Scopus
  40. I. Hattori, Y. Takagi, H. Nakamura et al., “Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice,” Antioxidants and Redox Signaling, vol. 6, no. 1, pp. 81–87, 2004. View at Google Scholar · View at Scopus
  41. T. Hoshino, H. Nakamura, M. Okamoto et al., “Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 9, pp. 1075–1083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Liu, H. Nakamura, K. Shioji et al., “Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice,” Circulation, vol. 110, no. 10, pp. 1276–1283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Ohashi, A. Nishio, H. Nakamura et al., “Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis,” American Journal of Physiology, vol. 290, no. 4, pp. G772–G781, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Okubo, S. Kosaka, N. Isowa et al., “Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung,” Journal of Thoracic and Cardiovascular Surgery, vol. 113, no. 1, pp. 1–9, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Okuyama, H. Nakamura, Y. Shimahara et al., “Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice,” Hepatology, vol. 37, no. 5, pp. 1015–1025, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Shioji, C. Kishimoto, H. Nakamura et al., “Overexpression of thioredoxin-1 in transgenic mice attenuates Adriamycin-induced cardiotoxicity,” Circulation, vol. 106, no. 11, pp. 1403–1409, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Hofer, C. Rosenhagen, H. Nakamura et al., “Thioredoxin in human and experimental sepsis,” Critical Care Medicine, vol. 37, no. 7, pp. 2155–2159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Nakamura, L. A. Herzenberg, J. Bai et al., “Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15143–15148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Tamaki, H. Nakamura, A. Nishio et al., “Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production,” Gastroenterology, vol. 131, no. 4, pp. 1110–1121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Al-Abed, D. Dabideen, B. Aljabari et al., “ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis,” Journal of Biological Chemistry, vol. 280, no. 44, pp. 36541–36544, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. S. K. Leaver, N. S. MacCallum, V. Pingle et al., “Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor,” Intensive Care Medicine, vol. 36, no. 2, pp. 336–341, 2009. View at Google Scholar
  52. A. Son, N. Kato, T. Horibe et al., “Direct association of thioredoxin-1 (TRX) with macrophage migration inhibitory factor (MIF): regulatory role of TRX on MIF internalization and signaling,” Antioxidants & Redox Signaling, vol. 11, pp. 2595–2605, 2009. View at Google Scholar